Subscribe

Recent Articles

Popular Posts

Site search

Follow Us

SBIR/STTR Reauthorization Act Passes in House; Biotech Industry is Big Winner

Written by on Thursday, April 24th, 2008 Print This Post Print This Post

The SBIR/STTR Reauthorization Act, H.R. 5819, has passed in the House and is now headed to the Senate; the biotech industry will be pleased to hear that the House has given them exactly what they asked for in this bill, according to Rick Shindell of the SBIR Gateway.

The SBIR Gateway reported on the House’s action as follows:

The voting on the amendments was a virtual "lovefest" with the results known ahead of time. There was absolutely no opposition on any amendments that were allowed to be offered. BIO’s VCs got everything they wanted and more with Sam Graves’ amendment to strike Title II (Venture Capital Investment Standards). Two important amendments were withdrawn (because they stood no chance of passage) and a few simply weren’t allowed to be accepted by the rules committee. . . .

Many SBIR advocates believe this is a bad bill that will be severely leveraged by the BIO/VC community. However, some other credible sources who deal in the DoD world think I may be presenting too severe of a worst case scenario.

SBIR Gateway reports that the highlights of the new bill include as follows:

  • The set aside remains at 2.5% SBIR and .3% STTR
  • 3% of the 2.5% will come off the top for agency administrative funds
  • Phase I Awards $300k Phase II Awards $2.2m
  • Agencies have the flexibility to award more $$ and consecutive phase IIs as they see fit
  • Ability to apply for a phase II award without having received a phase I award
  • Shortening of the time to receive the award
  • More frequent solicitations and topics (at agency discretion)
  • Notification of the right of a debrief
  • Establishment of an SBIR advisory board
  • Ability to crossover between SBIR and STTR
  • Increase in commercialization assistance funding
  • New FAST program funded at $10m

In addition, SBIR Gateway reports that the bill will include the following preferences and priorities:

  • Areas that have lost major source of employment
  • Preference to organizations making significant contributions towards energy efficiency
  • Priority to veteran companies
  • Special consideration to pressing transportation and infrastructure research activities
  • Special consideration for energy related research topics
  • Special consideration for rare-disease-related research topics
  • Priority to rural areas
  • Preference in FAST awards for SBDC applicants that are accredited for technology services  

Thus, it appears that the first round in this reauthorization battle goes to the biotech community.   We will keep you posted as to how the reauthorization battle unfolds in the Senate.

1,041 total views, 1 views today


© 2008-2015 The Prinz Law Office. All rights reserved.

The Prinz Law Office | Silicon Valley, CA | Los Angeles, CA | Orange County, CA | San Diego, CA | Atlanta, GA | Tel: 1.800.884.2124

Mailing Address: 117 Bernal Rd., Suite 70-110, San Jose, CA 95119; Silicon Valley Office: San Jose- 2033 Gateway Place, 5th Floor, San Jose, CA 95110 (408)884-2854; Los Angeles Office: 3110 Main St., Building C, Santa Monica, CA 90405 (310)907-9218; Orange County Office: 100 Spectrum Center Drive, 9th Floor, Irvine, CA 92618 (949)236-6777; San Diego Office: 4455 Murphy Canyon Road, Suite 100, San Diego, CA 92123 (619)354-2727 Atlanta Office: 1000 Parkwood Circle, Suite 900, Atlanta, Georgia 30339 (404)479-2470

Biotech Lawyer & Attorney: Serving Silicon Valley, San Jose, San Francisco, Santa Cruz, San Diego, Los Angeles, Orange County, Irvine, Anaheim, Santa Monica, Silicon Beach, Santa Barbara, Sacramento, Atlanta. Licensed in California and Georgia.
Follow

Get every new post delivered to your Inbox

Join other followers